AXITINIB Targets Gatekeeper-Mutant BCR-ABL1(T315I)-Driven Leukemia in a Distinct And Selective Fashion

被引：0
|
作者：
Pemovska, T. [1 ]
Johnson, E. [2 ]
Kontro, M. [3 ,4 ]
Repasky, G. A. [1 ]
Chen, J. [2 ]
Wells, P. [2 ]
Cronin, C. [2 ]
McTigue, M. [2 ]
Kallioniemi, O. [1 ]
Porkka, K. [3 ,4 ]
Murray, B. W. [2 ]
Wennerberg, K. [1 ]
机构：
[1] Univ Helsinki, FIMM, Helsinki, Finland
[2] Pfizer Worldwide Res & Dev, Oncol Res Unit, San Diego, CA USA
[3] Univ Helsinki, Cent Hosp, Ctr Comprehens Canc, Helsinki, Finland
[4] Univ Helsinki, Helsinki, Finland
来源：
ANNALS OF HEMATOLOGY | 2015年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
51
引用
收藏
页码：S90 / S91
页数：2
相关论文
共 50 条
  • [31] Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation
    Seiichi Okabe
    Tetsuzo Tauchi
    Yuko Tanaka
    Juri Sakuta
    Kazuma Ohyashiki
    Journal of Hematology & Oncology, 8
  • [32] Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Tanaka, Yuko
    Sakuta, Juri
    Ohyashiki, Kazuma
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [33] The clonal evolution of two distinct T315I positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report
    De Benedittis, Caterina
    Papayannidis, Cristina
    Venturi, Claudia
    Abbenante, Maria Chiara
    Paolini, Stefania
    Parisi, Sarah
    Sartor, Chiara
    Cavo, Michele
    Martinelli, Giovanni
    Soverini, Simona
    BMC CANCER, 2017, 17
  • [34] MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia
    Giles, F. J.
    Swords, R. T.
    Nagler, A.
    Hochhaus, A.
    Ottmann, O. G.
    Rizzieri, D. A.
    Talpaz, M.
    Clark, J.
    Watson, P.
    Xiao, A.
    Zhao, B.
    Bergstrom, D.
    Le Coutre, P. D.
    Freedman, S. J.
    Cortes, J. E.
    LEUKEMIA, 2013, 27 (01) : 113 - 117
  • [35] KF1601, a Novel Orally Bioavailable Inhibitor of BCR-ABL1 T315I without Inducing Thrombotic Microangiopathy
    Ahn, Sung-Min
    Kim, Dong-Wook
    BLOOD, 2023, 142
  • [36] Targeted inhibition of Gatekeeper variant "T315I" of BCR-ABL by a purine based ATP-competitive inhibitor
    Azam, Mohammad
    Shakespeare, William C.
    Sawyer, Tomi K.
    Daley, George Q.
    CANCER RESEARCH, 2006, 66 (08)
  • [37] MK-0457, a novel aurora kinase and BCR-ABL inhibitor, is active against BCR-ABL T315I mutant chronic myelogenous leukemia (CML).
    Giles, Francis
    Cortes, Jorge
    Bergstrom, Donald A.
    Xiao, Alan
    Bristow, Penny
    Jones, Dan
    Verstovsek, Srdan
    Thomas, Deborah
    Kantarjian, Hagop
    Freedman, Steven J.
    BLOOD, 2006, 108 (11) : 52A - 52A
  • [38] Bestinib, a novel Bcr-Abl inhibitor for Chronic Myeloid Leukemia, inhibits a wide array of Bcr-Abl mutants including imatinib resistant T315I mutant
    Gupta, Pranav
    Yang, Ke
    Wang, Fang
    Wang, Xiaokun
    Kathawala, Rishil J.
    Fu, Liwu
    Chen, Zhe Sheng
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S100 - S100
  • [39] Detection of BCR-ABL T315i Mutation in Imatinib Resistant Chronic Myeloid Leukemia Patients
    Mardziah, M.
    Salwati, S.
    Azlin, I
    Hafiza, A.
    Farisah, Noor A. R.
    Noraesah, M.
    Tumian, N. R.
    Wong, C. L.
    Azma, R. Z.
    MEDICINE AND HEALTH-KUALA LUMPUR, 2019, 14 (01): : 145 - 156
  • [40] Extramedullary Blast Crisis in a Patient with T315I BCR-ABL Mutated Chronic Myeloid Leukemia
    Zhang, Jingwen
    Zhang, Xiangzhong
    Lu, Ying
    Jiao, Ju
    Chen, Yuxin
    Lin, Dongjun
    CLINICAL LABORATORY, 2018, 64 (1-2) : 193 - 196
12345